Price T Rowe Associates Inc Lineage Cell Therapeutics, Inc. Transaction History

Price T Rowe Associates Inc

$869 Billion
Q3 2024

A detailed history of Price T Rowe Associates Inc transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 108,204 shares of LCTX stock, worth $69,250. This represents 0.0% of its overall portfolio holdings.

Number of Shares

108,204

Previous 165,394 34.58%

Holding current value

$69,250

Previous $164,000 40.24%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$0.8 - $1.12 $45,752 - $64,052	-57,190 Reduced 34.58%	108,204 $98,000
Q2 2024 Aug 14, 2024	BUY	$0.89 - $1.47 $3,631 - $5,997	4,080 Added 2.53%	165,394 $164,000
Q1 2024 May 15, 2024	BUY	$0.86 - $1.48 $60,559 - $104,218	70,418 Added 77.47%	161,314 $239,000
Q4 2023 Feb 14, 2024	BUY	$0.91 - $1.35 $5,059 - $7,506	5,560 Added 6.52%	90,896 $100,000
Q2 2023 Aug 14, 2023	SELL	$1.26 - $1.53 $4,742 - $5,758	-3,764 Reduced 4.22%	85,336 $121,000
Q3 2022 Nov 14, 2022	BUY	$1.13 - $1.77 $18,871 - $29,559	16,700 Added 23.07%	89,100 $101,000
Q2 2022 Aug 15, 2022	BUY	$1.12 - $1.61 $12,666 - $18,207	11,309 Added 18.51%	72,400 $114,000
Q1 2022 May 16, 2022	BUY	$1.21 - $2.48 $3,267 - $6,696	2,700 Added 4.62%	61,091 $94,000
Q4 2021 Feb 14, 2022	SELL	$1.84 - $2.68 $105,432 - $153,564	-57,300 Reduced 49.53%	58,391 $143,000
Q3 2021 Nov 15, 2021	BUY	$2.26 - $2.86 $140,029 - $177,205	61,960 Added 115.32%	115,691 $292,000
Q2 2021 Aug 16, 2021	BUY	$2.17 - $3.0 $21,550 - $29,793	9,931 Added 22.67%	53,731 $153,000
Q1 2021 May 17, 2021	BUY	$1.77 - $3.1 $77,526 - $135,780	43,800 New	43,800 $103,000

Others Institutions Holding LCTX

# of Institutions

121

Shares Held

94.2M

Call Options Held

63.8K

Put Options Held

View Full List

About Lineage Cell Therapeutics, Inc.

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $109M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

More about LCTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Lineage Cell Therapeutics, Inc. Transaction History